Results 21 to 30 of about 1,543,210 (202)

[Hepatorenal Syndrome]. [PDF]

open access: yesKorean J Gastroenterol, 2023
Hepatorenal syndrome (HRS) is a critical and potentially life-threatening complication of advanced liver disease, including cirrhosis. It is characterized by the development of renal dysfunction in the absence of underlying structural kidney pathology.
Choi JC, Yoo JJ.
europepmc   +3 more sources

Estudis sobre la insuficiència renal en la cirrosi hepàtica: Anàlisi del pronòstic i investigació en el tractament farmacològic de la síndrome hepatorenal [PDF]

open access: yes, 2013
[cat] Des que es va definir la síndrome hepatorenal (SHR), als anys 60 del segle passat, s’han fet grans progressos en el coneixement d’aquesta entitat.
Martín Llahí, Marta
core   +5 more sources

Hepatorenal syndrome: an update [PDF]

open access: yesSão Paulo Medical Journal, 2007
Hepatorenal syndrome (HRS) is the development of renal failure in patients with chronic previous liver disease, without clinical or laboratory evidence of previous kidney disease.
Tércio Genzini   +1 more
doaj   +4 more sources

Role of renal Duplex ultrasonography in evaluation of hepatorenal syndrome

open access: yesEgyptian Liver Journal, 2021
Background Hepatorenal syndrome is a potentially fatal complication of advanced liver disease. Markers for early diagnosis and identification of high-risk patients are lacking.
Mohamad Sherif Mogawer   +6 more
doaj   +1 more source

Contemporary management of pain in cirrhosis: Toward precision therapy for pain

open access: yesHepatology, EarlyView., 2022
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman   +4 more
wiley   +1 more source

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran   +17 more
wiley   +1 more source

Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS

open access: yesHepatology, EarlyView., 2022
The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck   +14 more
wiley   +1 more source

Establishment and evaluation of an early prediction model of hepatorenal syndrome in patients with decompensated hepatitis B cirrhosis

open access: yesBMC Gastroenterology, 2023
Background and aim In China, hepatorenal syndrome is a serious complication in the decompensated stage of hepatitis B cirrhosis, which requires early clinical intervention, so the early diagnosis of hepatorenal syndrome is crucial. This study establishes
Shouhao Wang   +8 more
doaj   +1 more source

Diagnostic and prognostic performance of urinary neutrophil gelatinase‐associated lipocalin in patients with cirrhosis and acute kidney injury

open access: yesHepatology, EarlyView., 2022
Diagnostic and prognostic ability of urinary NGAL in patients with cirrhosis and AKI. Abstract Background and Aims Acute kidney injury (AKI) commonly occurs in patients with decompensated cirrhosis. Urinary neutrophil gelatinase–associated lipocalin (uNGAL) could help discriminate between different etiologies of AKI.
Carmine Gambino   +14 more
wiley   +1 more source

Effect of rifaximin in the prevention of acute kidney injury and hepatorenal syndrome type II in Egyptian cirrhotic patients [PDF]

open access: yesZagazig University Medical Journal, 2021
Background: Hepatorenal syndrome type II and acute kidney injury found in 20% of cirrhotic patients. Rifaximin was found to reduce the frequency of hepatorenal syndrome type II and acute kidney injury in alcohol cirrhotic patients.
Ahmed El-Gebaly   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy